142 related articles for article (PubMed ID: 35033478)
1. Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
Moertl B; Dreyling M; Schmidt C; Hoster E; Schoel W; Bergwelt-Baildon MV; Berger K
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):474-482. PubMed ID: 35033478
[TBL] [Abstract][Full Text] [Related]
2. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
[TBL] [Abstract][Full Text] [Related]
3. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
[TBL] [Abstract][Full Text] [Related]
4. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
5. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
6. Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis.
Tsutsué S; Makita S; Yi J; Crawford B
PLoS One; 2022; 17(5):e0269169. PubMed ID: 35622820
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
[TBL] [Abstract][Full Text] [Related]
8. Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.
Tsutsué S; Makita S; Yi J; Crawford B
Future Oncol; 2021 Nov; 17(33):4511-4525. PubMed ID: 34414783
[No Abstract] [Full Text] [Related]
9. Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies.
Hamadani M; Liao L; Yang T; Chen L; Moskowitz C
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):373-381. PubMed ID: 34933826
[TBL] [Abstract][Full Text] [Related]
10. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
[TBL] [Abstract][Full Text] [Related]
15. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma.
Shi YF; Zhou SJ; Sun L; Yu K; Chen Y
Med Clin (Barc); 2020 Sep; 155(6):235-241. PubMed ID: 32173075
[TBL] [Abstract][Full Text] [Related]
16. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
17. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
18. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Joseph J; Ma J; Hennawy F; Abdulrazzaq MN; Saini N; Patel RD; Hosing CM; Alousi AM; Anderlini P; Popat UR; Qazilbash MH; Shpall EJ; Srour S; Kebriaei P; Bashir Q; Nastoupil LJ; Westin JR; Rondon G; Champlin RE; Andersson BS; Nieto Y; Muzzafar T; Ahmed S
Transplant Cell Ther; 2021 May; 27(5):404.e1-404.e5. PubMed ID: 33965178
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Ghobadi A; Munoz J; Westin JR; Locke FL; Miklos DB; Rapoport AP; Perales MA; Reagan PM; McGuirk JP; Jacobson CA; Kersten MJ; Avivi I; Peng A; Schupp M; To C; Oluwole OO
Blood Adv; 2024 Feb; ():. PubMed ID: 38315832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
